Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Avecho Biotechnology Limited
  6. News
  7. Summary
    AVE   AU0000047441

AVECHO BIOTECHNOLOGY LIMITED

(AVE)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Avecho Biotechnology Limited Receives Ethics Approval for Cbd Human Trial

04/12/2021 | 06:58pm EDT

Avecho Biotechnology Limited advise that it has received ethics approval for its Phase I clinical trial, that will characterise the absorption profile of cannabidiol (CBD) from its TPM®-enhanced pharmaceutical CBD product in healthy volunteers. Avecho's oral CBD formulation has already been demonstrated to increase the oral bioavailability of CBD in animal models when compared to standard CBD preparations. Increasing the absorption of cannabinoids will support the development of differentiated cannabinoid products on the market, with potential for greater therapeutic potential and/or reduced cost to patients. The Company is already participating in the CAClinics Observational Study (CACOS), Australia's largest running observational study of medicinal cannabis products in patients, to gather real world feedback on how this product will perform for a range of indications that currently utilise medicinal cannabis therapy. The study will measure the safety and absorption profile of the CBD product developed with TPM® and the data will form an integral part of a future TGA submission and drug label. The study will take place at CMAX in Adelaide with 16 healthy volunteers. The study will be a cross-over design comparing the absorption of CBD after consumption of soft-gel capsules at two different doses; 75 mg and 150 mg. These clinical doses were chosen to align with the TGA's down-scheduling of CBD, which has specified that future over-the- counter CBD products must have a maximum daily dose of 150 mg.


ę S&P Capital IQ 2021
All news about AVECHO BIOTECHNOLOGY LIMITED
10/04AVECHO BIOTECHNOLOGY : Begins Dosing Volunteers for Phase 1 Cannabidiol Clinical Trial
MT
10/03Avecho Biotechnology Limited Announces Dosing Commences for Phase I Human Clinical Tria..
CI
09/15AVECHO BIOTECHNOLOGY : Begins Enrolment for Phase 1 Cannabidiol Absorption Trial
MT
09/14Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption
CI
08/23Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, ..
CI
05/26Avecho Biotechnology to Discuss Cannabidiol Soft-Gel Product with Drug Regulator; Share..
MT
05/21AVECHO BIOTECHNOLOGY : Completes Cannabidiol Soft Gel Product Design; Shares Rally 13%
MT
05/20Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product
CI
05/04Avecho Biotechnology Limited Announces Resignation of Mr. David Segal as Director
CI
04/12AVECHO BIOTECHNOLOGY : Secures Ethics Approval for Cannabidiol Product Test on Humans
MT
More news
Financials
Sales 2020 0,38 M 0,29 M 0,29 M
Net income 2020 -2,63 M -1,96 M -1,96 M
Net cash 2020 1,71 M 1,27 M 1,27 M
P/E ratio 2020 -17,1x
Yield 2020 -
Capitalization 33,1 M 24,5 M 24,5 M
EV / Sales 2019 0,75x
EV / Sales 2020 116x
Nbr of Employees 15
Free-Float 69,3%
Chart AVECHO BIOTECHNOLOGY LIMITED
Duration : Period :
Avecho Biotechnology Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVECHO BIOTECHNOLOGY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Paul David Gavin Chief Executive & Scientific Officer
Melanie Jaye Leydin Chief Financial Officer & Secretary
Gregory Collier Executive Chairman
Roksan Libinaki Chief Operating Officer
Ross Thomas Murdoch Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AVECHO BIOTECHNOLOGY LIMITED-37.93%25
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414